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Abstract
Background: Increased arterial stiffness is a cardiovascular outcome of metabolic syndrome (MetS). The
chromosome 9p21 locus has been identified as a major locus for risk of coronary artery disease (CAD). The single
nucleotide polymorphism (SNP), rs1333049 on chromosome 9p21.3 has been strongly associated with CAD and
myocardial infarction. Increased arterial stiffness could be the link between the 9p21 polymorphism and increased
cardiovascular risk. Since the impact of a genetic polymorphism on arterial stiffness especially in Asian populations
has not been well defined, we aimed to investigate the association of arterial stiffness with rs 1333049 variant on
chromosome 9p21.3 in Thai subjects with and without MetS risk factors.
Methods: A total of 208 Thai subjects, aged 35–75 years, 135 with and 73 without MetS, according to IDF and
NCEP-ATPIII criteria, were included in this study. Aortic-femoral pulse wave velocity (afPWV), brachial-ankle pulse
wave velocity (baPWV) and aortic ankle pulse wave velocity (aaPWV) were measured and used as markers of arterial
stiffness. The chromosome 9p21.3 locus, represented by the rs 1333049 variant and blood biochemistry were
evaluated.
Results: Arterial stiffness was elevated in subjects with MetS when compared with nonMetS subjects. PWV,
especially afPWV increased progressively with increasing number of MetS risk factors (r = 0.322, P <0.001). We also
found that the frequency distribution of the rs1333049 genotypes is significantly associated with the afPWV
(P <0.05). In multivariate analyses, there was an association between homozygous C allele and afPWV (Odds ratio
(OR), 8.16; 95% confidence interval (CI), 1.91 to 34.90; P = 0.005), while the GC genotype was not related to afPWV
(OR, 1.79; 95% CI, 0.84 to 3.77; P = 0.129) when compared with the GG genotype.
Conclusions: Our findings demonstrate for the first time that arterial stiffness is associated with genetic
polymorphism in 9p21 and metabolic risk factors in a Thai population.
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Background
Metabolic syndrome (MetS) is defined as a clustering of
metabolic abnormalities including central obesity, hyper-
glycaemia, dyslipidaemia, hypertriglyceridaemia, and ele-
vated blood pressure [1]. MetS is now a major public
health problem with high prevalence in both developed
and developing countries [2]. Current estimates suggest
that, worldwide, about 20-30% of the population have
some form of this syndrome [3]. In Thailand, by 2006,
the prevalence of the MetS was about 19% in men and
27% in women [4]. Although environmental risk factors
contribute greatly to the development of MetS, genetic
factors also play an important role in its pathogenesis
[5-8]. A previous study in a Caribbean-Hispanic popula-
tion found that genetic factors contribute 24% to the
MetS after adjusting for age and sex [9]. In the past year,
several genome wide association studies have reported
associations between a region on chromosome 9p21.3
and risk of cardiovascular disease (CVD) [5]. The same
chromosomal region is also associated with type 2 dia-
betes (T2D) [10]. MetS is strongly associated with the
risk of CVD and T2D [11]. People with MetS have
higher all cause and cardiovascular mortality than those
without MetS.
Increased arterial stiffness, a pathological condition as-
sociated with vascular damage and or remodelling, is a
cardiovascular outcome of MetS [12-14]. It has been
shown to predict CVD morbidity and mortality in the
general population and also in T2D [12]. The SNP
rs1333049 on chromosome 9p21.3 has a particularly
strong association with carotid plaque formation [15],
abdominal aortic aneurysm [16], and predicts severity of
CAD [17]. Although the effect of MetS and its compo-
nents on arterial stiffness has been reported in the past,
this association has not been addressed in a Thai popula-
tion. Moreover, there has been little work describing the
association of genetic variation on chromosome 9p21.3
with arterial stiffness, especially in Asian nationals [18].
To shed light on a possible influence of these genetic
polymorphisms on arterial wall integrity, it is therefore
the aim of this study to investigate the association of rs
1333049 variant on chromosome 9p21 and arterial stiff-
ness in Thais with and without MetS risk factors.
Methods
Study population
A total of 208 subjects, 117 men and 91 women, aged
35–75 years, were recruited from the Outpatient Clinic
of Queen Sirikit Heart Center of Northeast Thailand,
Faculty of Medicine, Khon Kaen University, Khon Kaen
Province, Thailand. MetS was defined using a combin-
ation of the International Diabetes Federation (IDF) and
National Cholesterol Education Program Adult Treatment
Panel III (NCEP-ATPIII) criteria, with modification of
waist circumference (WC) for Asians [3,19,20]. This defin-
ition requires at least three of the following components:
(1) central obesity (WC ≥ 90 cm in men, and ≥ 80 cm in
women), (2) triglyceride concentration ≥ 150 mg/dL or
on triglyceride-lowering medication, (3) high-density
lipoprotein cholesterol (HDL-c) < 40 mg/dL in men
and < 50 mg/dL in women or on medication for low
HDL-cholesterol, (4) systolic blood pressure ≥ 130
mmHg and/or diastolic blood pressure ≥ 85 mmHg or
on antihypertensive medication, and (5) fasting glucose
concentration ≥ 100 mg/dL or drug treatment for ele-
vated glucose. NonMetS (healthy) individuals were de-
fined as those without history or diagnosis of MetS.
Informed consent was obtained from each participant.
The study protocol was approved by the Ethics Commit-
tee for Human Research of Khon Kaen University
(HE510414) and the study was conducted in accordance
with the Declaration of Helsinki.
Blood sample collection and anthropometric parameters
After 12-hour overnight fasting, blood was drawn from
an antecubital vein in the morning, and sent for analysis
within 3 hours. Biochemical markers in serum such as
fasting glucose, lipid profiles, and uric acid were
analysed by a Hitachi 917 automatic analyser (Roche
Diagnostics, Basel, Switzerland) at the Clinical Labora-
tory Unit of Queen Sirikit Heart Center of Northeastern
Thailand. High sensitivity C-reactive protein (hsCRP)
concentration was determined by means of high sensitiv-
ity particle enhanced immunonephelometry using the
BN ProSpecW System (Siemens Healthcare Diagnostics
Products GmbH, Marburg, Germany). Fasting serum in-
sulin was determined by a sandwich immunoassay with
commercial kits (Cisbio Bioassays, MA, USA). Insulin
resistance was estimated using the homeostasis model
assessment of insulin resistance (HOMA-IR) index, cal-
culated from the following expression: HOMA-IR = fasting
insulin (μU/mL) x fasting plasma glucose (mmol/L)/22.5.
Body mass index (BMI) was calculated as weight (kg)
divided by height (m)2. WC was measured midway
between the inferior margin of the last rib and the iliac
crest. Blood pressure was measured in the left arm of
supine subjects after 15 minutes of rest, using a Dinamap
Carescape v100 (GE Medical System, WI, USA).
Pulse wave velocity measurement
After blood pressure measurement, PWV was measured
according to a previously described method [21] using a
custom-built data acquisition system (Arterial Compli-
ance Monitor, Barts and The London’s School of Medi-
cine and Dentistry, UK), compatible with commercial
continuous wave Doppler probes (Dopplex MDII,
Huntleigh Healthcare, Cardiff, UK) and custom-made
reflectance photoplethysmography (PPG) probes. PWV
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was measured by placing two pulse sensing probes at ei-
ther end of arterial segment under study. Aortic-femoral
pulse wave velocity (afPWV), a good marker of aortic
stiffness , was measured by placing the proximal Doppler
probe (4 MHz) in the supraclavicular fossa of the sub-
ject’s neck at 45° to the subclavian arterial wall, angled
so that the ultrasound beam was directed toward the
aortic arch. The distal probe (reflectance PPG) was
placed over the femoral artery near the inguinal ligament.
For brachial-ankle pulse wave velocity (baPWV), the two
PPG probes were placed over the brachial artery and
dorsalis pedis artery, respectively. For the aortic-ankle
pulse wave velocity (aaPWV), the proximal Doppler
probe (4-MHz) was placed in the supraclavicular fossa
and the distal PPG probe was placed on the foot over the
dorsalis pedis artery. The pulse-wave contours from the
proximal and distal probes were captured at a sample
rate of 1 kHz and recorded for at least 3 min. Data were
analysed offline by custom-written software to detect the
feet of the proximal and distal pulse waves and to meas-
ure the time delay between them. Knowing the distance
between the proximal and distal sites and the propaga-
tion time delay between the artery waveforms, PWV was
calculated and expressed as m/s. We have previously
found [21] that the coefficients of variation values of
PWV between the intra- and inter-day measurements
were less than 5%.
DNA preparation and genotyping
The genotyping was performed in 171 subjects and these
were taken as a representative sample of the entire study
population. DNA was extracted from EDTA treated
blood samples using a Genomic DNA mini kit (Geneaid,
Taiwan) according to the manufacturer’s protocol. Geno-
typing for rs1333049 was performed using the TaqMan
SNP allelic discrimination genotyping assay (Applied
Biosystems, CA, USA). A total of 20 ng purified DNA
was amplified in a final volume of 20 μL per well in 96
well plates. The PCR conditions were; initial denatur-
ation at 95°C for 10 min, followed by 40 cycles at 92°C
for 15 sec and 60°C for 1 min. Post PCR allelic discrim-
ination was carried out by measuring allele-specific
fluorescence on an ABI prismW 7500 Sequence Detec-
tion System (Applied Biosystems) using the Sequence
Detection System software version 1.1. Genotyping was
successful in 96% of rs1333049 polymorphism.
Statistical analyses
Statistical comparison between MetS and nonMetS
groups was assessed by Student’s t-test or the Mann–
Whitney U test as appropriate. Pearson correlation ana-
lysis was used to assess relationships between PWV and
anthropometric variables, and also between PWV and
blood biochemistry. Comparisons among three or more
groups were evaluated by one way analysis of variance
(ANOVA) followed by Newman-Keuls post-hoc analysis.
Multiple logistic regression analysis was employed to
identify the risk factors associated with afPWV. Statistical
analyses were performed with Stata version 10 (Stata
Corp., College Station, TX, USA). A value of P <0.05 was
considered as significant.
Results
Characteristics of the study population
The baseline characteristics of subjects are shown in
Table 1. Their mean age was of 59.5 ± 10.3 years (range
35 to 75), 117 (56%) participants were male. Among
them, 135 participants were classified as MetS and 73, as
nonMetS. According to the IDF and NCEP-ATPIII cri-
teria, WC, systolic blood pressure, triglyceride, fasting
blood glucose, insulin, HOMA-IR were higher whereas
HDL-cholesterol was lower in MetS subjects. Moreover,
age, BMI, pulse pressure, and some parameters of blood
biochemistry, including hsCRP and uric acid were sig-
nificantly higher in MetS than nonMetS subjects.
PWV and relationship between anthropometry and blood
biochemistry
PWV values of each arterial segment (i.e. baPWV,
aaPWV, and afPWV) were significantly higher in MetS
than nonMetS subjects (Table 2). PWV at all three sites
was significantly correlated with age, systolic blood pres-
sure, and WC (Table 3). However, afPWV was more
strongly correlated with variables such as BMI, fasting
glucose, HOMA-IR, hsCRP and uric acid (Table 3) than
the PWV values measured in the arm and the leg. To
discern the relationship between PWV and MetS, the re-
lationship between PWV and the number of metabolic
risk factors for MetS was analysed, i.e. the presence of
insulin resistance, high blood pressure, high triglyceride,
low HDL-c, and high WC. baPWV, aaPWV and afPWV
increased with increasing number of MetS risk factors
(Figure 1). afPWV and aaPWV were significantly corre-
lated with the number of MetS risk factors, the strongest
correlation being with afPWV.
Polymorphism of rs1333049 in relation to PWV
The polymorphism of rs1333049 G>C has been reported
to be associated with increased risk of CVD. We wished
to determine whether the SNP could affect arterial elas-
ticity and thus subsequently increase the likelihood of
symptomatic CVD. The SNP rs1333049 G>C was
analysed in 171 subjects (114 MetS and 57 nonMetS).
The frequencies of the rs1333049 “G” and “C” alleles in
all subjects were 66.5% and 33.5%, respectively. In MetS
subjects, the frequencies of the “G” and “C” alleles were
68.5% and 31.4%, respectively and were not significantly
different from nonMetS subjects. In all subjects taken
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together, the frequency of the genotypes GG, GC and
CC were 46%, 41% and 13%, respectively, the distribu-
tion being consistent with the Hardy-Weinberg equilib-
rium, with Chi-squared = 0.769, P = 0.681.
The influence of rs1333049 polymorphism on arterial
elasticity was analyzed. There was an association of
rs1333049 genotypes with afPWV, but not with baPWV
or aaPWV. The effect of this was further analysed by
assigning subjects to a ‘low’ group if their PWV was less
than or equal to 11.0 m/s (based on the mean afPWV of
nonMetS subjects) and to a ‘high’ group, if greater than
11.0 m/s. The genotype of rs1333049 distribution in
the low and high PWV subjects is shown in the Table 4.
The distribution was significantly different between the
low and high afPWV groups with Chi-squared = 7.45,
P <0.05, suggesting a positive association between the
rs1333049 SNP and increased arterial stiffness.
Multivariate analysis of factors affecting PWV
Since the effect of age, gender, risk factors and
rs1333049 genotypes on PWV was strongest in the
aorto-femoral segment, we subjected these data to a
more detailed analysis. In univariate tests, afPWV was
significantly associated with age, risk factors and geno-
types (Table 5). Similarly, in multivariate analysis, in-
creased afPWV was associated with the advance in age
and increment in the number of MetS risk factors as
Table 1 Characteristics of the study subjects
Parameters All subjects (n = 208) NonMetS (n = 73) MetS (n = 135) P value
Age (y) 59.5 ± 10.3 55.3 ± 11.3 61.7 ± 9.0 <0.001
Gender (male (%)) 117 (56) 47 (64) 70 (52) 0.136
Waist circumference (cm) 88.6 ± 10.4 81.3 ± 9.5 92.5 ± 8.5 <0.001
Body mass index (kg/m2) 25.0 ± 3.7 23.1 ± 3.2 26.1 ± 3.4 <0.001
Systolic blood pressure (mmHg) 129 ± 17.0 121 ± 11.2 134 ± 17.7 <0.001
Diastolic blood pressure (mmHg) 73.6 ± 11.1 71.8 ± 9.6 74.6 ± 11.8 0.084
Pulse pressure (mmHg) 55.7 ± 13.7 48.7 ± 9.3 59.5 ± 14.2 <0.001
Heart rate (beats/min) 66.4 ± 12.0 66.4 ± 13.8 66.4 ± 11.0 0.880
Total cholesterol (mg/dL) 184 ± 45.9 180 ± 45.7 186 ± 46.0 0.396
Triglyceride (mg/dL) 181 ± 104 132 ± 66.0 208 ± 112 <0.001
HDL-cholesterol (mg/dL) 43.7 ± 12.6 48.7 ± 13.3 41.0 ± 11.4 <0.001
LDL-cholesterol (mg/dL) 104 ± 38.6 105 ± 40.9 104 ± 37.4 0.805
Fasting glucose (mg/dL) 108 ± 45.9 89.9 ± 17.0 119 ± 53.2 <0.001
Insulin (μIU/mL) 16.2 ± 9.6 13.3 ± 7.8 17.8 ± 10.1 <0.001
HOMA-IR 4.65 ± 4.6 2.96 ± 1.9 5.58 ± 5.3 <0.001
hsCRP (mg/L) 1.79 ± 2.0 1.44 ± 1.6 1.98 ± 2.1 0.015
Uric acid (mg/dL) 6.32 ± 1.8 5.90 ± 2.0 6.54 ± 1.7 0.003
All data are expressed as mean ± SD or number (%). HDL, high-density lipoprotein; LDL, low-density lipoprotein; HOMA-IR, homeostatic model assessment-insulin
resistance; hsCRP, high sensitivity C reactive protein. P value, nonMetS vs. MetS.
Table 2 Pulse wave velocities of each arterial segment in
non-metabolic and metabolic syndrome subjects
Pulse wave velocity NonMetS (n=73) MetS (n=135) P value
baPWV (m/s) 10.22 ± 3.2 11.25 ± 3.3 0.004
aaPWV (m/s) 11.08 ± 3.2 12.40 ± 2.8 <0.001
afPWV (m/s) 10.64 ± 4.9 13.88 ± 5.4 <0.001
All data are expressed as mean ± SD, baPWV, brachial-ankle pulse wave
velocity; aaPWV, aortic-ankle pulse wave velocity; afPWV, aortic-femoral pulse
wave velocity. P value, nonMetS vs. MetS.
Table 3 Correlations between pulse wave velocities and
anthropometric and blood chemistry variables
Parameters baPWV aaPWV afPWV
Age (years) 0.291† 0.358† 0.277†
Systolic blood pressure (mmHg) 0.212* 0.332† 0.242†
Diastolic blood pressure (mmHg) 0.153 0.140 0.139
Waist circumference (cm) 0.162* 0.197* 0.352†
Body mass index (kg/m2) −0.011 0.015 0.257†
Triglyceride (mg/dL) 0.001 −0.027 0.129
HDL-cholesterol (mg/dL) −0.065 −0.074 −0.114
Fasting glucose (mg/dL) −0.041 0.060 0.172*
HOMA-IR −0.012 0.108 0.166*
hsCRP (mg/L) 0.060 0.116 0.225*
Uric acid (mg/dL) 0.061 0.150 0.203*
HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment-insulin
resistance; hsCRP, high sensitivity C-reactive protein; baPWV, brachial-ankle
pulse wave velocity; aaPWV, aortic-ankle pulse wave velocity; afPWV, aortic-
femoral pulse wave velocity. * P <0.05; † P <0.001.
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shown, by the increased OR to 11.12 (95% CI: 2.20-
56.18) when risk factors comprised 5 components. Inter-
estingly, afPWV was also increased in relation to the
gene dose (“C”) effect (Table 5). The presence of the
“GC” or “CC” genotype was associated with increased
risk of developing high PWV with OR of 1.79 (95% CI:
0.84-3.77) and 8.16 (95% CI: 19.1-34.90) after adjusting
for gender, age and metabolic risk factors.
Discussion
This study demonstrates, for the first time, that SNP
rs1333049 on chromosome 9p21.3 is an important deter-
minant for the progression of increasing arterial stiff-
ness, especially that of the aorta, in a Thai population.
Increased afPWV and aaPWV are associated with in-
creasing number of MetS risk factors, indicating that a
clustering of MetS risk may interact synergistically to
affect central arterial stiffness. Previous studies have sug-
gested that arterial stiffening in MetS, particularly in dia-
betic individuals, is associated with elastic lamellae
fragmentation and calcification, increased collagen
cross-linking, low-grade inflammation, increased smooth
muscle basal tone and endothelial dysfunction [22-25].
These processes may be influenced by both genetic and
environmental factors [6-8,23]. As the integrity of the
aortic wall is dependent on effective load bearing by the
elastin collagen network, one could speculate that the
SNPs on chromosome 9p21.3 might affect the wall in-
tegrity either through increased elastin fracture, degrad-
ation due to enhanced matrix metalloprotease activity,
calcification or enhanced collagen production.
A previous study has reported that central arterial
stiffness, as measured by heart-femoral PWV (hfPWV)
was more closely associated with CAD, CVD and
peripheral arterial disease than peripheral arterial stiff-
ness [26]. hfPWV, carotid-femoral PWV (cfPWV) and
afPWV, as used in this study may all be regarded as
measures of ‘aortic’ stiffness since in all cases the major
part of the path traversed by the pulse wave is the aorta
and a recent consensus document confirms that cfPWV
is an acceptable estimate of aortic stiffness [27]. How-
ever, it should be noted that in older people the ascend-
ing aorta lengthens with age [28] as does the common
iliac artery, which comprises approximately the distal
third of the path [29], and this will add an error to the
path length measurements, leading to an overestimation of
PWV. Previously, a cut-off point of hfPWV at 11.18 m/s
and cfPWV at 12 m/s showed good discrimination in the
validation set on the Sphygmocor system and the Colins
system, respectively [30]. Deng et al. set a cut-off value of
cfPWV at ≥ 9 m/s to diagnose arteriosclerosis in patients
with essential hypertension [31] and more recently 10 m/s
has been proposed as the threshold above which there is
an increased risk of cardiovascular events [27]. In the
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Figure 1 Relationship between the number of metabolic risk
factors and pulse wave velocity for each arterial segment. The
solid line in each box represents the median value, short dashed line
represents the mean, the top and bottom of the box represent the
interquartile range, and the whiskers indicate the 5th and 95th
percentiles. The regression line was derived from the relationship
between the number of metabolic risk factors and PWV.
Table 4 Distribution of rs1333049 genotypes in relation
to afPWV
Aortic-femoral Number subjects (%) Total subjects
pulse wave velocity GG GC CC
< 11 m/s 40 (57) 27 (39) 3 (4) 70
≥11 m/s 39 (39) 45 (45) 17 (17) 101
Chi-square tests of goodness of fit, Chi-square with continuity correction = 7.45,
P <0.05.
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present study, we assessed aortic stiffness in all subjects
using the Arterial Compliance Monitor which measures
afPWV rather than cfPWV and chose to use our mean
value of afPWV (11 m/s). This is close to the values
recommended in the consensus document and revealed a
clear difference in the association between afPWV and
rs1333049 genotypes. We found that the frequency distri-
bution of the rs 1333049 genotypes is significantly associ-
ated with afPWV groups (P<0.05). We conclude that, in
spite of uncertainties in the precise value of PWV used to
dichotomise the data, there is a clear association between
polymorphism of rs1333049 and raised arterial stiffness.
In addition to the aforementioned association, we
found increased aortic stiffness in subjects homozygous
for the C-allele of rs 1333049 on chromosome 9p21.3,
after adjusting for age and the number of MetS risk fac-
tors. We suggest the SNP rs1333049 might be involved
with the progression of raised aortic stiffness in Thais,
although the underlying mechanisms by which SNP
rs1333049 on chromosome 9p21.3 contributes to this
progression remain unclear. Previous studies have sug-
gested that the chromosome 9p21 locus predicts CAD
and involves the initiation or facilitation of atheroscler-
osis [32,33]. Wang et al. demonstrated that rs 1333049
polymorphism is an independent determinant of coron-
ary plaque progression in a Chinese Han population
[34]. Moreover, it was found that chromosome 9p21
locus is associated with recurrent myocardial infarction
or cardiac death following an acute coronary event [35].
Taken together, the genetic variants in this 9p21 locus
increase the risk of CAD by promoting atherosclerosis
development and plaque instability.
A large noncoding RNA gene named ANRIL
(CDKN2B-AS) is expressed in several cells and tissues,
where a number of SNPs located at the 5’ end including
rs1333049 have been suggested to be associated with
CAD [36]. The ANRIL gene possibly coordinates tran-
scriptional regulation of 2 cyclin-dependent kinase in-
hibitors (p16/CDKN2A and p15/CDKN2B) under both
physiological and pathological conditions. A SNP
rs1333049 was located in a 190 kb region of the high
linkage disequilibrium, upstream both of p16/CDKN2A,
p15/CDKN2B and p14/ARF that code for p15 and p16
and p14ARF [36]. These proteins are involved in cell
cycle regulation, and also affect the atherosclerotic
process by inhibiting the transformation of tumour
growth factor-β, a well known tumour suppressor pro-
tein [37]. SNP rs1333049 has not only been reported to
increase the risk of CAD [38,39] but also of abdominal
aortic aneurysms [16,40], these diseases being preceded
by altered arterial stiffness. Therefore, our finding of the
homozygous CC genotype of SNP rs1333049 in subjects
with high aortic stiffness is in good agreement with
those observed in CVD patients.
Conclusions
We have observed that the SNP rs1333049 on chromo-
some 9p21 locus is associated with increased arterial
Table 5 Univariate and multivariate logistic regression models for predicting the central arterial stiffness in the study
subjects
afPWV Univariate model Multivariate model
Odds ratio 95% CI P Odds ratio 95% CI P
Gender Female: Male 0.812 0.44 - 1.49 0.50 0.75 0.35-1.58 0.50
Age
Quartile 1 (≤ 51 years) 1 1
Quartile 2 (52–59 years) 4.06 1.71 - 9.61 0.001 2.27 0.81 – 6.36 0.120
Quartile 3 (60–66 years) 4.71 1.85 - 11.99 0.001 2.55 0.78 – 8.40 0.123
Quartile 4 (≥ 67 years) 11.69 4.24 - 32.24 <0.001 7.88 2.45 – 25.3 0.001
Risk factor
≤ 1 1 1
2 1.83 0.63 - 5.34 0.267 1.36 0.35 - 5.23 0.685
3 3.38 1.33 - 8.59 0.011 2.42 0.74 - 7.91 0.144
4 7.71 2.89 - 20.55 <0.001 4.49 1.33 - 15.14 0.015
5 10.00 2.68 - 37.38 0.001 11.12 2.20 - 56.18 0.004
rs1333049
GG genotype 1 1
GC genotype 1.71 0.89 - 3.27 0.106 1.79 0.84 - 3.77 0.129
CC genotype 5.81 1.58 - 21.42 0.008 8.16 1.91 - 34.90 0.005
afPWV, aortic-femoral pulse wave velocity.
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stiffness in a Thai population. This association is
strengthened by the presence of MetS risk. Research on
this genetic polymorphism in a large population is re-
quired to investigate this association in more detail.
Moreover, a mechanistic study is also needed to clarify
the effect of the chromosome 9p21 locus on arterial
stiffening. Since MetS-associated arterial stiffening in-
creases cardiovascular risk, our findings add to the evi-
dence that management of MetS to prevent advanced
cardiovascular complications is clinically important.
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